Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502242 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 229
- Enrollment target
NCT00502242 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 229 participants.
The verdict
NCT00502242, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 229 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the efficacy of ramipril in preventing a urinary protein to creatinine ratio (U p/c) greater than 0.5 following conversion to sirolimus from a calcineurin inhibitor (CNI) in maintenance kidney transplant patients.
Interventions
- DRUG ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2007-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00502242
The ClinicalTrials.gov registry entry for NCT00502242 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ramipril is the first listed.
NCT00502242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00502242 about?
NCT00502242 is a clinical study titled "Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus". The primary objective of the study is to determine the efficacy of ramipril in preventing a urinary protein to creatinine ratio (U p/c) greater than 0.5 following conversion to sirolimus from a calcineurin inhibitor (CNI) in maintenance kidney transplant patients.
What is the current status of trial NCT00502242?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 229 participants. The study started on 2007-12. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00502242?
The interventions under investigation include: ramipril (DRUG).
Who is sponsoring clinical trial NCT00502242?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.